Clinical Guidelines for Management of Chronic Non-Communicable Diseases (NCDs): An Integrated Provider's Manual for Hypertension & Cardio-Vascular Diseases, Diabetes, Asthma & COPD, and Epilepsy

Objectives

The manual provides integrated clinical guidance for hypertension and other cardiovascular diseases, diabetes, asthma, chronic obstructive pulmonary disease and epilepsy in Malawi, with a core aim of preventing cardiovascular disease, reducing complications and extending life through appropriate diagnosis, risk stratification and treatment.[1]It focuses particularly on prevention and management across hypertension, ischaemic heart disease, acute coronary syndromes, stroke, heart failure, kidney disease and hypertensive disorders of pregnancy.[2][3][4][5]

• Identify hypertension through repeated, accurate blood-pressure measurement; investigate comorbidities and potential secondary causes; assess target-organ damage; and stratify cardiovascular risk before deciding whether treatment benefits outweigh harms.[1][6][7]
• Reduce cardiovascular risk through lifestyle modification, blood-pressure control, management of diabetes and cholesterol, smoking and alcohol cessation, physical activity, and indicated primary or secondary prevention with medicines such as aspirin.[7][2][8]
• Provide timely treatment for acute and chronic cardiovascular conditions, including hypertensive crises, angina, acute coronary syndromes, myocardial infarction, transient ischaemic attack, stroke and heart failure.[2][8][3][9][10]
• Prevent kidney-disease progression and complications through targeted blood-pressure management, avoidance of nephrotoxins, appropriate investigation, dietary measures and referral for possible dialysis when clinically indicated.[11][5]
• Improve maternal and foetal outcomes by recognising, monitoring and managing pregnancy-induced hypertension, pre-eclampsia and eclampsia, including stabilisation, seizure treatment and timely delivery where required.[5][12][13]
• Initiate rehabilitation early after stroke, identify treatable causes and provide long-term secondary prevention to limit disability and recurrent events.[9]

Implementation

Implementation is principally a facility-based, risk-stratified clinical delivery model spanning primary, secondary and tertiary care. The Ministry of Health, through its Non-communicable Diseases and Mental Health Unit, is the named institutional owner of the manual.[1]The supplied text does not specify wider governance arrangements, workforce roles, implementation partners, budgets or a formal programme monitoring framework.[1][7][4]

• Measure blood pressure for all adults at every facility visit, with particular attention to people over 30 years, those with obesity, diabetes, relevant family histories or HIV, smokers, people with harmful alcohol use, and pregnant women.[1]Diagnose hypertension from three readings of at least 140/90 mmHg over at least two days, except where severe readings require same-day diagnosis and treatment.[1]
• Ensure reliable assessment by resting the patient, supporting the arm at heart level, using an appropriate cuff and repeating raised readings; undertake baseline glucose, urinalysis, creatinine and HIV testing, with further tests when comorbidity or secondary hypertension is suspected.[1][6]
• Combine lifestyle measures with stepwise antihypertensive medicines, favouring once-daily regimens where possible.[7]Start immediate drug treatment for high-risk patients, while using three to six months of lifestyle modification before escalation for selected moderate-risk patients.[7]
• Adapt treatment to diabetes, renal disease, heart failure, prior myocardial infarction and pregnancy, including avoidance of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers during pregnancy.[14]
• Establish reverse referral for stable patients between tertiary, secondary and primary care, while using secondary or tertiary facilities for specified investigations and referring externally for percutaneous coronary angiography.[7][3]
• Manage acute severe illness in hospital, high-dependency or intensive-care settings as appropriate, using monitoring, oxygen, intravenous or oral treatment, reperfusion or thrombolysis for eligible myocardial infarction, and escalation to ventilation or inotropic support for acute heart failure when needed.[2][3][10]
• Deliver stroke care through assessment of swallowing, hydration, glucose, fever and complications; begin physiotherapy and speech therapy on the first day; and refer for rehabilitation or specialist care where indicated.[9]
• Manage obstetric emergencies through admission or referral of severe cases, frequent maternal and foetal monitoring, magnesium sulphate for eclampsia, toxicity surveillance, antenatal corticosteroids before 34 weeks where indicated, and decisions on delivery according to maternal and foetal status.[12][13]
• Monitor clinical response through adherence checks at every visit, blood-pressure targets, renal-function checks after starting angiotensin-converting enzyme inhibitors, and condition-specific follow-up such as review four weeks after acute coronary syndrome discharge.[7][8]

Monitoring & Evaluation

Monitoring is principally clinical and facility-based, covering diagnosis, treatment response, medicine safety, acute-care assessment and referral; the supplied extracts do not establish a formal programme monitoring and evaluation framework, population surveillance system, routine reporting schedule, evaluation methodology or accountability arrangements.[1][6][7][2][8][3][9][10][4][11][5][12]

• Measure blood pressure for all adults at every facility visit, particularly people with recognised cardiovascular risk factors or pregnancy, and diagnose hypertension from three readings of at least 140/90 mmHg over at least two days, except for severe readings requiring same-day diagnosis and treatment.[1]
• Check adherence at every visit through patient self-report of missed medication days, and assess whether treatment achieves the general target below 140/90 mmHg or lower targets for diabetes, renal impairment, proteinuria and diabetic nephropathy.[7]
• Monitor creatinine before, where possible, and two to four weeks after starting an angiotensin-converting enzyme inhibitor; discontinue the medicine if creatinine rises by more than 30%.[7]
• Assess hypertensive emergencies through bilateral and postural blood-pressure measurement where possible, fundoscopy, neurological and chest examination, urine testing, electrocardiography and oxygen saturation; review hypertensive urgency after one week.[2]
• Review patients four weeks after discharge from acute coronary syndrome or acute myocardial infarction care to assess continuing angina, cardiac failure and blood-pressure control.[8][3]
• Use electrocardiography, chest radiography, glucose, full blood count, urea and electrolytes, cardiac enzymes, lipid profile and echocardiography for acute cardiac assessment, with some investigations reserved for higher-level facilities or external referral.[3]
• Investigate stroke with glucose, HIV, syphilis, full blood count, urea, creatinine and electrocardiography to identify atrial fibrillation; use brain imaging to distinguish ischaemic from haemorrhagic stroke where available.[9]
• Monitor heart failure and kidney disease using ejection fraction, blood pressure, urea, creatinine, estimated glomerular filtration rate, electrolytes, urine testing, electrocardiography and renal ultrasound, and use defined clinical triggers to consider acute dialysis.[4][11]
• Calculate glomerular filtration rate during chronic kidney disease clinic visits and refer symptomatic patients with a rate of 20–30 ml/min for possible dialysis.[5]
• Monitor pre-eclampsia through daily weight and urine dipstick checks, four-hourly blood-pressure measurement, gestational and foetal-wellbeing assessment, and ultrasound; investigate abnormal blood count, renal, liver and electrolyte results and refer to a central hospital where results are deranged.[12]
• Monitor severe eclampsia with blood-pressure checks every 15 minutes until controlled and hourly thereafter, foetal-heart monitoring every 30 minutes, and surveillance for magnesium sulphate toxicity through patellar reflexes, respiratory rate and urine output.[12][13]
• Maintain respiratory rate at or above 16 breaths per minute and urinary output at or above 25 millilitres per hour during magnesium sulphate treatment; stop magnesium sulphate and administer intravenous calcium gluconate if toxicity occurs.[13]

Costing & Financing

No costs, budgets, financing sources, resource-mobilisation arrangements, funding gaps or economic assumptions are specified in the supplied extracts.[1][7][2][3][4][5][13]

• Require clinical inputs including blood-pressure equipment, laboratory investigations, medicines, intensive or high-dependency care, oxygen, monitoring, rehabilitation, dialysis referral and specialist referral, but provide no monetary values, allocations or funding mechanisms for these inputs.[3][9][10]
• Require obstetric emergency resources including magnesium sulphate, calcium gluconate, oxygen, intravenous access, catheterisation, foetal monitoring, ultrasound or cardiotocography, corticosteroids and delivery care, but do not cost these requirements.[12][13]